WordNet

the 15th letter of the Roman alphabet (同)o
the blood group whose red cells carry neither the A nor B antigens; "people with type O blood are universal donors" (同)type_O, group O

PrepTutorEJDIC

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/12/15 10:49:29」(JST)

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 化学的胸膜癒着術 chemical pleurodesis
2. 小児の双極性障害：治療法の選択に関する概要 pediatric bipolar disorder overview of choosing treatment
3. 新生児における胸水のマネージメント management of pleural effusions in the neonate
4. 下顎、口、口腔、および咽頭の先天異常 congenital anomalies of the jaw mouth oral cavity and pharynx
5. 乳糜胸症のマネージメント management of chylothorax

Chemical pleurodesis for prolonged postoperative air leak in primary spontaneous pneumothorax.

How CH1, Tsai TM1, Kuo SW1, Huang PM1, Hsu HH1, Lee JM1, Chen JS2, Lai HS3.
Journal of the Formosan Medical Association = Taiwan yi zhi.J Formos Med Assoc.2014 May;113(5):284-90. doi: 10.1016/j.jfma.2012.12.016. Epub 2013 Feb 8.
BACKGROUND/PURPOSE: Prolonged air leak is the most common complication after thoracoscopic operation for primary spontaneous pneumothorax (PSP), and the role of chemical pleurodesis in treating air leaks remains unclear. This study evaluated the safety and efficacy of chemical pleurodesis with a co
PMID 24746114

Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.

Ohtake J1, Ohkuri T1, Togashi Y2, Kitamura H1, Okuno K3, Nishimura T4.
Immunology letters.Immunol Lett.2014 Apr 30. pii: S0165-2478(14)00079-0. doi: 10.1016/j.imlet.2014.04.010. [Epub ahead of print]
We identified novel helper epitope peptides of Survivin cancer antigen, which are presented to both HLA-DRB1*01:01 and DQB1*06:01. The helper epitope also contained three distinct Survivin-killer epitopes presented to HLA-A*02:01 and A*24:02. This 19 amino-acids epitope peptide (SU18) induced weak r
PMID 24794408

Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis.

Kobayashi M1, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, Abe H, Tanii M, Okamoto M, Tsujitani SI, Yusa S, Ishidao T, Kishimoto J, Shibamoto Y, Nagaya M, Yonemitsu Y; The DC Vaccine Study Group at the Japan Society of Innovative Cell Therapy (J-SICT).
Cancer immunology, immunotherapy : CII.Cancer Immunol Immunother.2014 Apr 29. [Epub ahead of print]
OBJECTIVE: Dendritic cell (DC)-based cancer vaccines may have a significant benefit to patients with advanced pancreatic cancer. However, variations among clinical studies make it difficult to compare clinical outcomes. Here, we identified factors that determined the clinical benefits by analyzing d
PMID 24777613